ViGenCell, Inc. 308080

KRX · South Korea · Health Technology

KRW 5,810.00-40.00 (-0.68%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Company news

Yahoo FinanceApr 21, 2026

ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026

ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, today announced that results from its Phase 2 clinical study of VT-EBV-N have been selected for an oral presentation at the ASCO Annual Meeting 2026.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.